Contributed to the discovery and preclinical development of novel antimicrobial compounds, including LptA Thanatin derivatives, OMPTA (LPS/BamA), and LptD/E (Murepavadin), covering early discovery to preclinical profiling. Conducted ADMET characterisation alongside extensive antimicrobial susceptibility testing (MIC, MBC, kill kinetics, resistance liability) using MDR/XDR strains. Performed mode-of-action studies and optimised established high-throughput workflows, enhancing assay efficiency and implementing robust QC checkpoints. Co-inventor of Antimicrobial Peptidomimetics, with significant contributions to assay development strategies addressing resistance emergence. Supported clinical-stage activities through evaluation of patient recruitment strategies. Managed BSL-2 laboratory operations, including facility oversight, procurement, inventory, and compliance. Collaborated across multidisciplinary teams and contributed to training and knowledge transfer within the organisation.